开立医疗(300633) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥430,012,001.93, a decrease of 10.29% compared to ¥479,333,865.45 in the same period last year[4] - Net profit attributable to shareholders was ¥8,074,620.52, down 91.94% from ¥100,190,827.63 year-on-year[4] - Total operating revenue for the current period is ¥430,012,001.93, a decrease of 10.3% from ¥479,333,865.45 in the previous period[17] - Net profit for the current period is ¥8,074,620.52, down 91.9% from ¥100,190,827.63 in the previous period[18] - Basic earnings per share decreased to ¥0.0187 from ¥0.2326, reflecting a significant decline in profitability[18] - The weighted average return on equity was 0.26%, down from 3.13% in the same period last year, indicating a significant decline in profitability[4] Cash Flow - The net cash flow from operating activities was -¥284,864,541.91, representing a decline of 899.07% compared to -¥28,513,064.73 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥284,864,541.91, compared to a smaller outflow of ¥28,513,064.73 in the previous period[20] - The company reported a cash inflow from investment activities of ¥499,535,533.27, a significant increase compared to ¥17,769.69 in the previous period[20] - Net cash flow from investment activities was 320,146,424.73, compared to a negative cash flow of -72,622,271.05 in the previous period[21] - Net cash flow from financing activities was -154,416,991.98, a significant decrease compared to a positive cash flow of 226,745,799.91 in the previous period[21] - Cash inflow from financing activities was 21,167,720.37, down from 259,332,185.06 in the previous period[21] - The net increase in cash and cash equivalents was -118,050,845.31, contrasting with an increase of 126,702,284.38 in the previous period[21] - Cash paid for debt repayment was 168,918,309.64, indicating a significant cash outflow in financing activities[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,995,840,487.69, a decrease of 7.35% from ¥4,312,997,155.23 at the end of the previous year[5] - Total current assets decreased from CNY 2,974,995,087.77 to CNY 2,645,522,089.15, a reduction of approximately 11%[14] - Total liabilities decreased to ¥871,322,477.26 from ¥1,204,774,675.82, reflecting a reduction in financial obligations[16] - Total equity attributable to shareholders increased to ¥3,124,518,010.43 from ¥3,108,222,479.41, showing a slight growth in shareholder value[16] Investments and R&D - R&D expenses increased by 23.70% to ¥125,724,100.00, reflecting the company's commitment to new product development[9] - Research and development expenses increased to ¥125,724,109.43, up 23.6% from ¥101,637,595.01 in the previous period, indicating a focus on innovation[17] - The company reported a significant increase in investment income, which rose by 150.19% to ¥979,200.00, attributed to higher returns from financial products[9] - The cash flow from investment activities showed a net increase of 540.84%, amounting to ¥320,146,400.00, due to more redemptions of financial products than purchases[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,519[10] - The top two shareholders, Chen Zhiqiang and Wu Kunxiang, each hold 22.12% of shares, totaling 95,725,200 shares, both of which are pledged[10] Other Information - The company received government subsidies amounting to ¥1,266,210.55, contributing positively to its financial performance[6] - The company has no preferred shareholders or changes in restricted shares during the reporting period[12] - The company did not undergo an audit for the first quarter report[22] - The new accounting standards will be implemented starting from 2025[22]